Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 30 · above the Ichimoku cloud · RSI 51 · MACD below its signal
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.6 | 2.3 | -1.5 | -0.8 | -4.5 | 0.6 | 7.0 | 9.2 | 2.1 | 0.0 | +16.5% | ||
| 2025 | 43.4 | 30.6 | -3.5 | 10.4 | -15.3 | 19.5 | 28.8 | -0.7 | -3.6 | -6.4 | 2.1 | 3.7 | +146.8% |
| 2024 | 6.5 | 8.1 | -4.1 | -15.2 | -8.8 | -4.7 | -20.1 | 31.0 | -11.4 | 12.1 | -5.2 | 1.8 | −18.3% |
| 2023 | 2.3 | -17.3 | -0.4 | -1.4 | 37.9 | -17.5 | 8.9 | -1.0 | -4.6 | -3.4 | -6.5 | -2.1 | −14.0% |
| 2022 | -5.5 | 0.8 | -0.2 | -13.9 | -9.3 | 6.4 | 5.1 | 16.1 | -15.0 | 0.1 | 6.3 | -19.0 | −29.3% |
| 2021 | 31.2 | 30.0 | -1.1 | 4.5 | -15.9 | 31.7 | 0.2 | -7.6 | -9.0 | -7.4 | -15.5 | 12.1 | +44.5% |
| 2020 | 26.3 | -31.0 | -31.0 | 31.2 | -6.3 | -6.5 | 7.2 | 1.4 | -2.7 | -19.5 | 20.4 | 1.4 | −28.0% |
| 2019 | 1.2 | -3.9 | -10.6 | -9.0 | 14.0 | -18.7 | 2.4 | 13.1 | -18.0 | -18.2 | 10.8 | −36.9% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Sosiak (Nicholas)Senior Officer of Issuer | Acquisition in the public market at price 1.23 per share. | 16.8K | $20.63K |
| Feb 10, 2026 | Krivorot (Zohar)Director of Issuer | Disposition under a prospectus exemption at price 1.55 per share. | 333.3K | $515.67K |
| Jan 26, 2026 | Olds (Donald John)Director of Issuer | — | 12K | — |
| Jan 26, 2026 | Olds (Donald John)Director of Issuer | — | 12K | — |
| Jan 18, 2026 | Olds (Donald John)Director of Issuer | — | 19K | — |
| Jan 18, 2026 | Olds (Donald John)Director of Issuer | — | 19K | — |
| Jan 1, 2026 | Sosiak (Nicholas)Senior Officer of Issuer | Compensation for services at price 1.28 per share. | 312.5K | $398.44K |
| Dec 31, 2025 | Krivorot (Zohar)Director of Issuer | — | 468.8K | — |
| Dec 7, 2025 | Fox (Mary)Director of Issuer | — | 15K | — |
| Dec 7, 2025 | Kay (Jack M.)Director of Issuer | — | 15K | — |
| Dec 7, 2025 | Olds (Donald John)Director of Issuer | — | 35K | — |
| Dec 7, 2025 | Stern (Derek Elan)Director of Issuer | — | 25K | — |
None of the 29 investors followed here reported a position in LOVFF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LOVFF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No analyst coverage for this instrument.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.